After investing 1.5 billion over three years to build a Global research and development headquarters, can Zhejiang Orient Gene Biotech win this "turnaround battle"?

① Zhejiang Orient Gene Biotech spent 0.29 billion yuan to acquire land in Zhangjiang, planning to build a global digital research and development innovation headquarters project with a total investment of 1.5 billion yuan, expected to achieve annual sales revenue of 1.5 billion yuan upon reaching production capacity. ② After the demand for nucleic acid testing declined, Zhejiang Orient Gene Biotech encountered a performance "slump", remaining in a net loss of over 260 million yuan until the first three quarters of 2024.

cls.cnDec 13 03:28 ET

Former Alibaba CEO Wei Zhe joins sansure biotech inc. Latest response: will not involve business related to mergers and acquisitions by Sanshong.

①Wei Zhe expressed that the reason for joining sansure biotech inc. was to deeply empower the medical industry and gain in-depth understanding of the medical industry; ②He recently posted on his Moments saying that his ideas are highly consistent with sansure biotech inc. and the company's director and general manager, and he will deeply cultivate the sinking medical system and layout the blueprint for going global; ③At the end of last year, Wei Zhe and his founded Jia Yu Capital began to get involved in the medical health field, and announced the establishment of Jia Yu-Ziniu Medical Fund with Ziniu Fund.

cls.cnDec 1 22:01 ET

Tj Darentang USD: Wang Lei succeeds Zhang Mingrui as chairman, the company's development global strategy "will not change" | Express announcement

① Zhang Mingrui has applied to resign from the positions of tj darentang usd chairman, director, and chairman of the Global Strategy Committee due to work-related reasons. ② Wang Lei, the general manager of the company, will take over as chairman, with company officials stating that the enterprise's development strategy "will not change".

cls.cnNov 26 08:20 ET

tj darentang usd: Planning to sell 13% of the shares of Zhongmei SmithKline, still awaiting approval from the antitrust review | Direct hit on the shareholders' meeting

① Today's tj darentang shareholder meeting approved the proposal to sell a 13% stake in Sino-US Tianjin Schering Pharmaceutical Co., Ltd. (referred to as: Sino-US Schering). The company's chairman, Zhang Mingrui, stated: "Sino-US Schering is an outstanding company, and this stake sale is mainly due to the expiration of the 40-year cooperation period." ② The sale of the stake still requires approval from He Liyang after anti-monopoly review by the State Administration for Market Regulation.

cls.cnNov 22 06:16 ET

Zhangzhou pientzehuang pharmaceutical "curved" acquisition of Fujian cosunter pharmaceutical? The innovative drugs sector sees the reappearance of traditional chinese medicine industry players | Read the announcement quickly.

Fujian Cosunter Pharmaceutical announced that the Yuanshan Fund intends to become a shareholder with more than 5% stake in the company through a transfer payment of nearly 0.2 billion yuan. The partners of the Yuanshan Fund consist of a wholly state-owned company and a wholly-owned subsidiary of zhangzhou pientzehuang pharmaceutical, among which the investment from zhangzhou pientzehuang pharmaceutical is the largest limited partner in the fund.

cls.cnNov 15 11:14 ET

Pharmaceutical business shrinks, livzon pharmaceutical group inc. revenue declines year-on-year in the first three quarters | interpretations

1. In the first three quarters of this year, livzon pharmaceutical group inc.'s revenue decreased by a single-digit percentage compared to the same period last year, while net profit attributable to shareholders maintained positive growth year-on-year; 2. The revenue of the pharmaceutical sector, which contributed the most, declined; 3. Semaglutide has been submitted for marketing approval for the indication of diabetes, and the development of weight loss indication has entered phase III clinical trials.

cls.cnOct 23 09:27 ET